Please assess the completion status of the following clinical trial:

Trial Title: Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects will be eligible if the following criteria are met:~* Ability to provide written informed consent and comply with study assessments for the full duration of the study.~* Predominantly hemorrhagic subfoveal CNV (at least 50% of the lesion composed of hemorrhage) from age-related macular degeneration (AMD) resulting in visual acuity of 20/40 or worse.~* Age greater than 50 years.~* Participant must have media clear enough to permit fundus photography, fluorescein angiography, and optical coherence tomography.~Exclusion Criteria:~Subjects who meet any of the following criteria will be excluded from this study:~* Known hypersensitivity to humanized monoclonal antibodies~* History (within past 6 months) or evidence of severe cardiac disease (apparent in electrocardiogram abnormalities, clinical history of unstable angina, acute coronary syndrome, myocardial infarction, revascularization procedure within 6 months prior to baseline, atrial or ventricular tachyarrhythmias requiring ongoing treatment).~* History of stroke within 6 months of study entry.~* Current acute ocular or periocular infection.~* Any major surgical procedure within one month of study entry.~* Known serious allergies to fluorescein dye.~* Previous participation in a clinical trial (for either eye) involving anti-angiogenic drugs (pegaptanib, ranibizumab, anecortave acetate, Protein Kinase C inhibitors, etc) within last 6 months.~* Previous intravitreal drug delivery (e.g., intravitreal corticosteroid injection or device implantation) in the study eye within the last 6 months.~* History of subfoveal laser treatment in the study eye.~* History of other visually-limiting conditions such as optic neuropathy, amblyopia, choroidal neovascularization due to causes other than AMD in the study eye.~* Ocular inflammation (including trace or above) in the study eye.~* Inability to comply with study or follow up procedures.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): 0.3 mg/0.05 ml dose of ranibizumab
- B (Type: EXPERIMENTAL): 0.5 mg/0.05 ml dose of ranibizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).